TransThera secures $881.5M Neurocrine deal for NLRP3 inhibitor
TransThera
Small Molecule Innovative Drug Research, Development, and Manufacturing
Neurocrine Biosciences
Developer of Drugs for Neurological and Endocrine Related Diseases
On November 3, TransThera announced that it had entered into a royalty-bearing patent transfer and research collaboration agreement with Neurocrine Biosciences to develop NLRP3 inhibitors for the treatment of various diseases.
Under the agreement, Neurocrine will obtain exclusive rights to develop, manufacture, and commercialize NLRP3 inhibitors from TransThera's NLRP3 drug platform outside Greater China, while TransThera retains exclusive rights within Greater China.
TransThera will be eligible to receive an upfront payment and, based on Neurocrine's development and commercial progress, may receive additional milestone payments tied to R&D and sales achievements. The total potential value of the agreement could reach up to $881.5 million.
TransThera is dedicated to the discovery and development of innovative small-molecule therapies for oncology, inflammatory, and cardiovascular diseases. The company was listed on the Main Board of the Hong Kong Stock Exchange on June 23, 2025, and currently has no commercialized products. One of its pipeline candidates, TT-02332, is a novel, highly potent, and selective NLRP3 inhibitor in the preclinical research stage, being developed for the treatment of metabolic and inflammatory disorders.
The NLRP3 inflammasome is a multiprotein complex within myeloid cells. Its overactivation can lead to insulin resistance, chronic low-grade inflammation (such as the persistent inflammatory state seen in obesity), and tissue damage. Research indicates that inhibiting NLRP3 can reduce the release of inflammatory factors and decrease reactive oxygen species (ROS) production, thereby improving the cellular metabolic environment. This mechanism positions NLRP3 as a potential therapeutic target in areas including cancer, inflammatory bowel disease, nonalcoholic steatohepatitis (NASH), and cardiovascular diseases. To date, no NLRP3-targeting drug has been approved for marketing globally.
TransThera's NLRP3 drug platform enables precise modulation of inflammasome activation through the design of small-molecule inhibitors. Compared to antibody-based therapies, small-molecule drugs offer advantages such as oral administration and the ability to cross the blood-brain barrier, making them more suitable for long-term management of chronic conditions. Furthermore, the platform's accumulated expertise in compound screening and structural optimization provides a solid technological foundation for developing candidate drugs with high efficacy and low toxicity.
In preclinical studies, TT-02332 has demonstrated promising efficacy across multiple disease animal models and established clear target engagement as well as pharmacokinetic/pharmacodynamic (PK/PD) correlations.
Concurrently, preclinical data have revealed that TT-02332 possesses favorable pharmacokinetic properties and physicochemical drugability. Recently completed exploratory toxicology studies involving long-term repeated administration in two species indicated its excellent safety profile and wide therapeutic window.
TransThera has announced the initiation of IND-enabling studies for TT-02332, marking its imminent transition into the clinical development stage.